Drug intelligence / Profile preview

3-ethyl-2-(4-hydroxyphenyl)-2H-indazol-5-ol

Development stage: Unknown
Modality: Small Molecules

Overview

3-Ethyl-2-(4-hydroxyphenyl)-2H-indazol-5-ol is a synthetic small molecule belonging to the class of phenylpyrazoles and aromatic heteropolycyclic compounds[1][3]. It has been studied as an experimental compound, with reported activity as an inhibitor of the estrogen receptor and possible interaction with nuclear receptor coactivator 2[4]. Its precise mechanism of action, clinical indications, and therapeutic applications remain largely uncharacterized in public databases. The compound is not approved for medical use and is primarily referenced in chemical and pharmacological research contexts.

Other names: 3-Ethyl-2-(4-hydroxyphenyl)-2H-indazol-5-ol3-Ethyl-2-(4-hydroxyphenyl)indazol-5-ol

Targets

ESR2 (ERβ)ESR1 (ERα)

Beyond the preview

Go deeper on 3-ethyl-2-(4-hydroxyphenyl)-2H-indazol-5-ol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 3-ethyl-2-(4-hydroxyphenyl)-2H-indazol-5-ol.

Explore the full profile